List of Immuno-Oncology Companies in Canada - 7

Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with platform technologies in Immunotherapy and Immuno-Oncology. These platforms under development treat auto-immune disease indications and cancer. The company’s drug products use our proprietary recombinant human alpha fetoprotein (AFP).

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licenced to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47. DOS47 is our patented oncology platform technology that offers a new and revolutionary approach to the debilitation and destruction of cancer cells. Helix is led by an experienced Management team with excellent pharmaceutical development expertise and proven business skills. The group is committed in developing novel medicines through DOS47 platform technology.

Immune Biosolutions is a clinical stage biotech company specializing in discovering and engineering avian and human antibodies for therapeutic and diagnostic applications. Our cutting-edge techniques, including phage display and single B cell screening technologies, enable us to engineer custom-fit immunotherapeutic agents. Our discovery platform is available for biotech and pharma partners, providing access to highly conserved mammalian lineage targets and opening up new possibilities for innovative therapeutics. Our biomanufacturing capacity, which has already supported successful internal clinical trials, is also available for partners in a fee-for-service model. Our internal pipeline includes several discovery programs for various cancer and infectious disease indications. Through our platform, we generate diverse antibodies with high binding affinity and novel paratopes, paving the way for exciting new approaches to treating difficult proteins.

ME Therapeutics is a Biotechnology company that specializes in Immuno Oncology, focusing on treating previously untreatable cancers by targeting the immune system.

Qu Biologics is a Vancouver-based, private, clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel proprietary immunotherapy platform. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many diseases including cancer and inflammatory bowel disease (Crohn's disease, ulcerative colitis). SSIs aim to restore immune function and have potential broad applicability across a wide variety chronic diseases. The company has initiated three clinical trials in Crohn's disease, ulcerative colitis and lung cancer. Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally. We are always interested in talented biotechnology professionals and know that some of the best team members can be found when you’re not looking for them. For Qu, finding the right team member is not about matching a resume to a checklist of skills, it’s about integrity and character. If you have big ideas, love a fast-paced innovative environment and you’re up for the challenge, we want to hear from you. Send us your resume and a detailed cover letter telling us about yourself and how you feel you could contribute.